{"title":"Mirabegron use in the treatment of overactive bladder symptoms","authors":"G Alessandro Digesu PhD, MD, Michelle Gore RGN, Vik Khullar MD, MRCOG","doi":"10.1002/fps.97","DOIUrl":null,"url":null,"abstract":"<p>Beta-3 adrenoreceptors have been proposed as a target in the treatment of OAB due to their role in the mediation of bladder smooth muscle relaxation. Mirabegron is an oral medication that selectively targets beta-3 adrenoreceptors and has been shown to reduce rhythmic abnormal detrusor contractions in animal models. In this Drug profile the authors present the clinical data relating to its efficacy and adverse effects and discuss its potential place in the treatment of OAB. Copyright © 2013 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"13 3","pages":"10-13"},"PeriodicalIF":0.0000,"publicationDate":"2013-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.97","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.97","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
Beta-3 adrenoreceptors have been proposed as a target in the treatment of OAB due to their role in the mediation of bladder smooth muscle relaxation. Mirabegron is an oral medication that selectively targets beta-3 adrenoreceptors and has been shown to reduce rhythmic abnormal detrusor contractions in animal models. In this Drug profile the authors present the clinical data relating to its efficacy and adverse effects and discuss its potential place in the treatment of OAB. Copyright © 2013 John Wiley & Sons, Ltd.
Mirabegron用于治疗膀胱过度活动症状
由于β -3肾上腺素受体在膀胱平滑肌松弛中的作用，已被认为是治疗OAB的靶点。Mirabegron是一种选择性靶向β -3肾上腺素受体的口服药物，在动物模型中已被证明可以减少有节奏的异常逼尿肌收缩。在本药物简介中，作者介绍了有关其疗效和不良反应的临床数据，并讨论了其在治疗OAB中的潜在地位。版权所有©2013 John Wiley &儿子,有限公司
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
